title: Comment: defining cure in primary CNS lymphoma.
abstract: Primary CNS lymphoma (PCNSL), a type of extranodal non-Hodgkin lymphoma, is a potentially curable brain cancer. Ongoing randomized trials assessing treatments for PCNSL will ultimately establish a standard of care. Until that time, practitioners have multiple treatment options from which to choose. In this report, the authors provide long-term follow-up data from a phase 2 clinical trial in newly diagnosed PCNSL patients, ages 18-70, treated with MATILDE chemotherapy followed by whole-brain radiation therapy (WBRT).(1) The MATILDE regimen, like all induction chemotherapy currently utilized for PCNSL, includes methotrexate, the single most effective agent against PCNSL. Following chemotherapy, patients received a consolidative WBRT dose based on their initial response to chemotherapy.
authors.affiliation: From the Departments of Neurology and Radiation Oncology, Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston.
authors.forename: Tracy T
authors.initials: TT
authors.lastname: Batchelor
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male